Sorrento buys into ADCs with $12M deal; CardioDx postpones $92M IPO;

@FierceBiotech: Baxter bets $60M on Cell Therapeutics' blood cancer drug. Article | Follow @FierceBiotech

@JohnCFierce: Vanda jumps again as FDA panel smiles on sleep-disorder drug. More | Follow @JohnCFierce

@DamianFierce: ICYMI: Sanofi gets mixed FDA blessing for MS drug Lemtrada. Story | Follow @DamianFierce

@EmilyMFierce: From FierceBiotech Research: Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg. Article | Follow @EmilyMFierce

> Sorrento Therapeutics picked up biotech Concortis BioSystems for about $12 million, absorbing the company's antibody-drug conjugate technology. News

> Despite ongoing investigations and mounting scrutiny, Big Pharma has hardly given up on China, and both Johnson & Johnson ($JNJ) and Merck KGaA are plotting expansions in the country. Article

> Diagnostics outfit CardioDx is the latest life sciences company to postpone its IPO, holding off on a planned $92 million debut. Story

Medical Device News

@FierceMedDev: Trending on FierceMedicalDevices: Report: J&J plans layoffs, revamp to jumpstart diabetes arm. Story | Follow @FierceMedDev

@MarkHFierce: NeuroPace won the FDA's blessing for a neurostimulation implant to treat epilepsy. More | Follow @MarkHFierce

@MichaelGFierce: Next-gen sequencing tech from GenapSys nets $37M round. Item | Follow @MichaelGFierce

> In a blow to Edwards, German court restores Medtronic's right to sell heart valve. Article

> As other IPOs move forward, CardioDx pulls back. More

> Kimberly-Clark seeks to spin off healthcare, medical devices arm. News

Pharma News

@FiercePharma: So, if you're not among the 103K people who have already, check it out. Report | Follow @FiercePharma

@EricPFierce: With a market as big as China, you can't let a bribery case scare you away. J&J, Merck to build new plants. More | Follow @EricPFierce

@CarlyHFierce: Tufts University report: 71% of revenue from the top 10 best-selling meds last year came from biotech products. More | Follow @CarlyHFierce

> GSK expanding further in India with £85M facility, CEO Witty says. News

> Drugmakers confront new pay-to-delay cases under new rules. Report

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.